ClinicalTrials.gg
CompletedNCT06834295Updated May 28, 2025

A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir

A Phase 1/2 interventional study of Vapendavir in Healthy Males, sponsored by Altesa Biosciences, Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Altesa Biosciences, Inc. · Phase 1/2, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

The goal of this clinical trial is to assess how the body processes, breaks down and removes a new test medicine (vapendavir) from the body in healthy male participants.The main question it aims to answer is how the body handles the test medicine. In order to do that, the test medicine will be radiolabeled to track the test medicine in the body.

Healthy male participants who meet entry criteria will be admitted to the clinic for a duration of approximately 9 days (Day -1 to Day 8). Participants will be admitted in the evening on the day before dosing (Day -1). Participants will take a single oral dose of radiolabeled vapendavir on Day 1 and have samples collected and safety tests completed during various times throughout their stay in the the clinic. The safety tests will provide additional information on the safety and tolerability of the test medicine.

02

Conditions studied

  • Healthy Males

Keywords

  • ADME Study in Healthy Males
03

In context

Lead sponsor

Altesa Biosciences, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must provide written
  • Must be willing and able to communicate and participate in the whole study
  • Participants must demonstrate their ability to swallow 8 capsules
  • Aged 30 to 65 years inclusive at the time of signing informed consent
  • Must agree to adhere to the study requirements
  • Healthy male participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12- lead , and laboratory safety tests without any abnormalities
  • (BMI) of 18.0 to 35.0 kg/m2 as measured at screening
  • Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion criteria

Exclusion Criteria:

  • Serious adverse reaction or serious to any drug or formulation
  • Presence or history of allergy requiring treatment, as judged by the investigator
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator
  • Acute diarrhea or constipation in the 7 days before the predicted Day 1
  • Participants who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
  • Clinically significant abnormal laboratory values at screening as judged by the investigator
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) 1 and 2 antibody results
  • Evidence of renal impairment at screening
  • Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
  • Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
  • Participants who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 3 g of paracetamol per day) in the 14 days before dosing
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption >21 units per week (1 unit = 1⁄2 pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 = 125 mL glass of wine, depending on type)
  • A confirmed positive alcohol breath test
  • Current smokers and those who have smoked within the last 12 months
  • Current users of e-cigarettes or nicotine replacement products and those who have used these products within the last 12 months
  • A confirmed breath carbon monoxide reading of greater than 10 ppm
  • Confirmed positive drugs of abuse test result
  • Male participants with pregnant or lactating partners
  • Participants who are, or are immediate family members of, a study site or sponsor or employee
  • Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Open-label, non-randomized, single-dose of [14C]Vapendavir

    Single oral dose of \[14C\]Vapendavir

    Drug: Vapendavir

Interventions

  • Single oral dose of \[14C\]vapendavir

06

What researchers measure

Primary outcomes

  1. To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])vapendavir.

    Mass balance recovery of total radioactivity in all excreta (urine and feces): CumAe and Cum%Ae.

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).

Secondary outcomes

  1. To determine the routes and rates of elimination of [14C]vapendavir.

    Determination of routes and rates of elimination of \[14C\]vapendavir by Ae, %Ae, CumAe and Cum%Ae by interval.

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).

  2. To perform metabolite profiling and structural identification from plasma, urine and fecal samples.

    Identification of the chemical structure of each metabolite accounting for greater than or equal to 10% of circulating radioactivity in plasma ("AUC pool"), and accounting for greater than or equal to 10% of the dose in urine (from urine pools) and feces (fecal homogenate pools) will be performed.

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).

  3. To identify the chemical structure of each metabolite accounting for more than 10% of circulating total radioactivity or accounting for 10% or more of the dose in excreta.

    Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity or accounting for 10% or more of the dose in excreta.

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).

  4. To evaluate the extent of distribution of total radioactivity into blood cells.

    Evaluation of whole blood: plasma concentration ratios for total radioactivity.

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).

  5. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Time prior to the first measurable concentration (Tlag)

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).

  6. To provide additional safety and tolerability information for vapendavir by assessing: incidence of adverse events (AEs), new physical examination findings and change from baseline for vital signs, electrocardiograms (ECGs), and laboratory safety tests.

    Descriptive summaries for all safety data (AEs, vital signs, ECGs and safety laboratory assessments) will be provided.

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).

  7. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Time of maximum observed concentration (Tmax)

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  8. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Maximum observed concentration (Cmax)

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  9. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Area under the curve from time 0 to the time of last measurable concentration (AUC (0-last))

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  10. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Area under the curve from time 0 extrapolated to infinity (AUC (0-inf))

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  11. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Terminal elimination half-life (T1/2)

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  12. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    First order rate constant associated with the terminal (log-linear) portion of the curve (Ke)

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  13. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F)

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  14. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the cure extrapolated to infinity (AUCextrap)

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  15. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Mean residence time from time 0 to time of the last measurable concentration (MRT(0-last))

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  16. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Mean residence time from time 0 to extrapolated to infinity (MRT(0-inf))

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days)

  17. To further explore the oral pharmacokinetic (PK) of vapendavir. To characterise the PK of vapendavir and total radioactivity in plasma following a single oral dose of [14C]vapendavir.

    Apparent volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vd/F).

    Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, UK NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Mar 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 19, 2025
StartActual
Mar 12, 2025
Primary completionActual
Mar 23, 2025
CompletionActual
Mar 23, 2025
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06834295
Lead sponsor
Altesa Biosciences, Inc.
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Mar 12, 2025
Primary completion
Mar 23, 2025
Completion
Mar 23, 2025
Last update
May 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vapendavir

Start the discussion